A recent study suggests that patients who come off new slimming jabs like Wegovy and Mounjaro tend to recover reduced body mass far faster than those who stop conventional lifestyle plans.
Research printed in a prominent medical journal demonstrates that while obese individuals often shed a large proportion of their total mass while on the medication, the weight comes back at an estimated rate of 0.8 kg per month once they quit.
"Users purchasing such drugs should be aware of the danger of quick weight regain when the treatment concludes," cautioned researcher Dr. Susan Jebb.
Such speed of regain implies a return to starting weight within about a year and a half.
Analyzing Therapies
The research, which looked at dozens of studies involving thousands of participants, contrasted the effects of the injectable medications with other pills.
The team point out that people who shed pounds through lifestyle changes alone usually experience a less rapid creep back—around 100 grams monthly—after stopping.
Explaining the Rapid Rebound
Doctors propose the mode of action of the injections accounts for the accelerated weight return.
These medications mimic a natural hormone called GLP-1, which helps regulate hunger.
"Artificially providing GLP-1 concentrations far above than the body's typical production may cause the system to produce less of its endogenous hormone, and may also reduce sensitivity to its effects," explained Dr. Adam Collins, a nutrition researcher.
"Withdrawal of this GLP-1 'fix' results in appetite is uncontrolled, making excessive eating a significant risk."
A Lifelong Issue?
Health authorities advise the jabs for individuals with obesity-related health risks, alongside prescribed lifestyle changes.
Many experts argue that, due to the likelihood of relapse, the therapy might need to be long-term.
This perspective is reinforced by drug manufacturers, who say that the results "emphasize the long-term character of excess weight," comparing it to managing diseases like hypertension.
Patient Testimonies
Individuals who have come off the medication describe a intense resurgence of hunger.
"I experienced something that goes on and I was suddenly starving," said a patient.
This challenge is worsened if individuals have not adopted permanent dietary or behavioural modifications during therapy.
Significant Interest
Figures show that a significant number of people in the UK have tried these injections in the last 12 months, with demand remaining high.
- Adoption is greater among women than males.
- The 40s and 50s age group shows the highest level of interest.
- A large proportion access the drugs through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while these medications are effective agents for shedding pounds, they are not a magic fix and lasting health benefits relies on integrated lifestyle support.
